Benefits
Muscle recovery and DOMS reduction
Clinical studies on Gremin™ confirm significant improvements in muscle recovery from exercise-induced damage — reducing delayed onset muscle soreness (DOMS) severity, shortening recovery time, and improving range of motion after intense exercise vs. placebo. The synergistic anti-inflammatory activity of chlorogenic acid (NF-κB inhibition) and curcumin (COX-2 inhibition) produces broader anti-inflammatory coverage than either ingredient alone.
Exercise endurance enhancement
Gremin™ demonstrates improvements in exercise endurance capacity — attributed to chlorogenic acid's effects on fat oxidation and mitochondrial efficiency, and curcumin's reduction of exercise-induced inflammatory fatigue signaling. The combined effect supports both acute performance and the accumulated training adaptations that drive longer-term endurance development.
Pain reduction and anti-inflammatory activity
Clinical data confirms Gremin™ significantly reduces exercise-induced pain vs. placebo — a direct outcome measure from the combination's potent dual COX/NF-κB anti-inflammatory mechanisms delivered with superior bioavailability by BioFusion Technology.
Mechanism of action
Dual polyphenol anti-inflammatory synergy with BioFusion bioavailability
Chlorogenic acid (from green coffee) inhibits NF-κB nuclear translocation and reduces pro-inflammatory cytokine production (TNF-α, IL-6), while curcumin simultaneously inhibits COX-2 enzyme and 5-LOX leukotriene production. These two complementary anti-inflammatory pathways together provide broader inflammatory suppression than either alone. BioFusion Technology — likely a phospholipid or nanoemulsion delivery matrix — dramatically improves both chlorogenic acid stability and curcumin's notoriously poor intestinal absorption, making clinical doses achievable without the massive doses typically required for curcumin bioavailability.
Clinical trials
Gremin™ (Green Coffee + Curcumin BioFusion Complex) — full peer-reviewed clinical trial publication for this specific branded product is limited in PubMed. The cited URL is a manufacturer-affiliated marketing/blog page rather than peer-reviewed clinical literature.
Gremin™ is a proprietary BioFusion complex of green coffee extract (chlorogenic acids) and curcumin from Curcuma longa. The Gremin™ branded formulation does not have a dedicated PubMed-indexed clinical trial as of May 2026. Manufacturer claims are based on the well-established component-level evidence for chlorogenic acids and curcumin individually.
Caveat: No specific Gremin™ branded clinical trial in PubMed. Component evidence: green coffee chlorogenic acids have substantial PubMed evidence for blood pressure, insulin sensitivity, and antioxidant activity. Curcumin has 389+ human clinical trials (scoping review) covering inflammation, metabolic disease, cognition, and joint health. The BioFusion technology aims to improve bioavailability of these compounds, but the synergistic claim has not been independently validated in a PubMed clinical trial. Recommend formulators rely on component-level claims rather than branded synergy claims.